NAVARRO Rafael Alemany

Retina Specialist Institut Microcirurgia Ocular, Barcelona, Spain

Experience in clinical studies :
  • Sub-investigador in: A randomized, controlled study on the efficacy and safety of Sandostatin LAR in the therapy of patients with moderately severe or severe non –proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR). NOVARTIS. Hospital de la Santa Creu i Sant Pau 2000.
  • Sub-investigador in: A multicenter, randomized, doubled masked,controlled study to evaluate the saffety and efficacy of an intravitreal fluocinolone acetonide (0.5 or 2 mg) implant compared to standard therapy in patients with non infectious uveitis affecting posterior segment of the eye . BAUSCH AND LOMB. Hospital de la Santa Creu i Sant Pau 2002.
  • Sub-investigator in: Diabetic Retinopathy Candesartan Trials DIRECT. ASTRAZENECA. Hospital de la Santa Creu i Sant Pau, 2001.
  • Sub-investigator in: Ensayo fase II/III multicéntrico aleatorio, doble-enmascarado, de escalada de dosis, controlado, comparativo y de grupos paralelos para establecer la seguridad y eficacia de inyecciones intravítreas de eye001 (Aptámero anti-VEGF polietilen glicosilado) administradas cada 6 semanas durante 54 semanas en pacientes con degeneración macular exudativa asociada a la edad. EOP1003.EYETECH PHARMACEUTICALS. Instituto de Microcirugía Ocular de Barcelona 2001.
  • Sub-investigator in clinical trial C-01-99: ANECORTAVE. ALCON. .Instituto de Microcirugía Ocular de Barcelona 2003.
  • Sub-investigator in B7A-MC- MBDL clinical trial: Reducción en la aparición del edema macular diabético que amenaza el centro de la macula con LY333531. Lillly. Instituto de microcirugía ocular. Barcelona 2004.
  • Sub-investigator in B7A-MC-MBCU clinical trial: Reducción en la aparición del edema macular diabético que amenaza el centro de la macula con LY333531. Lilly. Instituto de microcirugía ocular. Barcelona 2005.
  • Sub-investigator in EXCITE clinical trial CRFB002A2302 (Ranibizumab). Novartis. Instituto de microcirugía ocular. Barcelona 2006.
  • Sub investigador in C-02-60 (ARMD). AART. ALCON. Instituto de microcirugía ocular. Barcelona 2005.
  • Sub-Investigator in 1123-THG/MIVI-II/TG-MV002 ( microplasmin in diabetic macular edema). Thrombogenics Ltd. Instituto de microcirugía ocular. Barcelona 2007.
  • Principal investigador in Clinical Trial 206207-010-01 (posurdex in diabetic macular edema) . Allergan. Instituto de microcirugía ocular. Barcelona 2007.
  • Principal investigator in clinical trial FAME allimera. Diabetic Macular Edema. Instituto de microcirugía ocular. Barcelona 2007.
  • Co-investigator in IMI clinical trial. Epiretinal Implants in Retinitis Pigmentosa. Instituto de microcirugía ocular. Barcelona 2008

Last Published (presented) papers (international):

  1. Navarro R, Gris O, Broc L, Corcostegui B. “Bilateral giant retinal tear following posterior chamber phakic intraocular lens implantation” Journal of Refractive Surgery. May-jun;21(3):298-300. 2005.
  2. Valverde D, Riveiro-Alvarez R, Bernal S, Jakson K, Baiget M, Navarro R, Ayuso C.” Microarray-based mutation analysis of the ABCA4 gene in Spanish patients with Stargardt disease: evidence of a prevalent mutated allele”. Mol Vis 2006 Aug11;12:902-8.
  3. Rafael Navarro, MD; Ricardo Casaroli-Marano, MD; Carlos Mateo, MD; Oscar Gris, MD; Alfredo Adan, MD; Borja Corcóstegui, MD. OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN ALPORT SYNDROME. Retinal cases and brief reports. Vol 2, nº 1, page 47-9
  4. Adan A, Casaroli-Marano RP, Gris O, Navarro R, Bitrian E, Pelegrin L, Sanchez-Dalmau B. “Pathological findings in the lens capsules and intraocular lens in chronic pseudophakic endophthalmitis: an electron microscopy study”. Eye. 2006 Oct 13
  5. Navarro R, Mateo C, Corcóstegui B, Baiget M, Bernal S. R .“Choroidal Neovascularization associated with Goldmann-Favre syndrome”. Retinal Cases and brief reports.Vol 1, nº 2. Page 5-6
  6. Burés-Jelstrup A, Navarro R, Mateo C, Adan A, Corcóstegui B. Detection of ciliary body detachment with anterior segment optical coherence tomography. Acta Ophthalmol Scand. 2008 Jan 24.
  7. Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization.Retina. 2007 Nov-Dec;27(9):1180-6.
  8. Adán A, Solé M, Corcostegui B, Navarro R, Burés A. Cytological vitreous findings in a patient with infantile neurological cutaneous and articular (CINCA) syndrome. Br J Ophthalmol. 2007 Jan;91(1):121-2.
  9. Bernal S, Solans T, Gamundi MJ, Hernan I, de Jorge L, Carballo M, Navarro R, Tizzano E, Ayuso C, Baiget M.,. Analysis of the involvement of the NR2E3 gene in autosomal recessive retinal dystrophies.Clin Genet. 2008 Apr;73(4):360-6. Epub 2008 Feb 20.
  10. Ronan SM, Yoganathan P, Chien FY, Corcóstegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, López M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina. 2007 Jun;27(5):535-40.
  11. García-Arumí J, Corcóstegui IA, Navarro R, Zapata MA, Berrocal MH. Vitreoretinal surgery without schisis cavity excision for the management of juvenile X linked retinoschisis. Br J Ophthalmol. 2008 Nov;92(11):1558-60.

A – “Evaluation and treatment guidelines in the management of retinal vein occlusions”. 14th Congress of the European Society of Ophthalmology. Madrid. June 2003.
B – “Hereditary retinoschisis: management of complications”. Euretina. Barcelona. May 2005.
C – “Current concepts in X- linked retinoschisis”. Euretina. Vienna. 2008.